Most powerful obesity drug yet: People lost up to 25% of weight in trial
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
The short version
- Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations.
- Patients with obesity on the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks, and an average of 30 percent after an extension period to 104 weeks.
- Overall, more than a third of participants taking retatrutide lost 30 percent or more of their weight.
What happened
The data is likely to only ratchet up the anticipation for the drug among the millions of Americans with obesity. Retatrutide is being developed by pharmaceutical giant Eli Lilly, which also makes tirzepatide, a potent dual-acting treatment for obesity (Zepbound) and type 2 diabetes (Mounjaro).
Why it matters
Both medications build on GLP-1-based obesity drug semaglutide (Ozempic/Wegovy) from pharmaceutical company Novo Nordisk.
Summary by Nerd News Network. Read the full article at Ars Technica via the links above and below.